Abstract:ATP-binding cassette (ABC) transporters are a large family of proteins involved in membrane transport of a wide variety of substrates. Among them, ABCB1, also known as MDR-1 or P-glycoprotein (P-gp), is the most characterized. By exporting xenobiotics out of the cell, P-gp activity can affect the ADME properties of several drugs. Moreover, P-gp has been found to mediate multidrug resistance in cancer cells. Thus, the inhibition of P-gp activity may lead to increased absorption and/or intracellular accumulation of co-administered drugs, enhancing their effectiveness. Using the human cryoEM 3D structure of the P-gp in the inhibitor-bound intermediate form (PDBID: 6qee), approximately 200'000 commercially available natural compounds from the ZINC database were virtually screened. To build a model able to discriminate between substrate and inhibitors, two datasets of compounds with known activity, including P-gp inhibitors, substrates, and inactive molecules were also docked. The best docking pose of selected substrates and inhibitors were used to generate 3D common feature pharmacophoric models that were combined with the Autodock Vina binding energy values to prioritize compounds for visual inspection. With this consensus approach, 13 potential candidates were identified and then tested for their ability to inhibit P-gp, using zosuquidar, a P-gp inhibitor of clinical use, as a reference drug. Eight compounds were found to be active with 6 of them having an IC50 lower than 5 µM in a membrane-based ATPase activity assay. Moreover, the P-gp inhibitory activity was also confirmed by two different cell-based in vitro methods. These results demonstrate the ability of the combined structure-based pharmacophore modeling and docking-based virtual screening approach to predict novel hit compounds with inhibitory activity toward P-gp. The resulting chemical scaffolds could serve as inspiration for the optimization of novel and more potent P-gp inhibitors.

Structure-ATPase Activity Relationship of Rhodamine Derivatives as Potent Inhibitors of P-Glycoprotein CmABCB1

Research Advance on P-glycoprotein Inhibitors and the Structure-Activity Relationship

Structural Basis for Substrate and Inhibitor Recognition of Human Multidrug Transporter MRP4

Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives As Potent Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance.

Structure-activity Relationship and Mechanism of Flavonoids on the Inhibitory Activity of P-glycoprotein (P-Gp)-mediated Transport of Rhodamine123 and Daunorubicin in P-gp Overexpressed Human Mouth Epidermal Carcinoma (KB/MDR) Cells

Hz08 Inhibits the Multi-Drug Resistance on Multiple Sites As the Substrate of P-Glycoprotein

Computational Insights Into Allosteric Conformational Modulation Of P-Glycoprotein By Substrate And Inhibitor Binding

Discovery to Solve Multidrug Resistance: Design, Synthesis, and Biological Evaluation of Novel Agents

R6G narrows BmrA conformational spectrum for a more efficient use of ATP

Design, Synthesis and Biological Evaluation of LBM-A5 Derivatives As Potent P-glycoprotein-mediated Multidrug Resistance Inhibitors.

Effect of Five Novel 5-Substituted Tetrandrine Derivatives on P-glycoprotein-mediated Inhibition and Transport in Caco-2 Cells

Exploring the Dynamics of the ABCB1 Membrane Transporter P-glycoprotein in the Presence of ATP and Active/Non-active Compounds through Molecular Dynamics Simulations

Structure activity relationships and the binding mode of quinolinone-pyrimidine hybrids as reversal agents of multidrug resistance mediated by P-gp

Design, Synthesis and Biological Evaluation of Novel Triazole-Core Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance

Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding

Mechanistic insights into P-glycoprotein ligand transport and inhibition revealed by enhanced molecular dynamics simulations

Quantitative Structure⁻Activity Relationships for the Flavonoid-Mediated Inhibition of P-Glycoprotein in KB/MDR1 Cells.

Consensus screening for a challenging target: the quest for P-glycoprotein inhibitors

Design, Synthesis and Biological Evaluation of N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxamide Derivatives As Novel P-glycoprotein Inhibitors Reversing Multidrug Resistance

Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1h)yl)ethyl)phenyl)quinazolin-4- Amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance

Designing potent inhibitors against the multidrug resistance P-glycoprotein